Literature DB >> 10661066

Intermittent subcutaneous injections of pain medication: effectiveness, manageability, and satisfaction.

M Letizia1, J Shenk, T D Jones.   

Abstract

This study describes the use of intermittent subcutaneous injections of medications for pain control in a home hospice program. Six questionnaires were used to collect data over a one-year time period on the 52 patients who received medications by this route. Eighty-four percent of those patients had a diagnosis of cancer; patients received hospice care for a mean of 25 days. On average, intermittent subcutaneous medications were instituted three days prior to the patient's death. The main indication for this route was difficulty swallowing. Morphine was the most frequently used drug; side effects from the medication and problems with the route were rarely reported. Demographic information was collected on both the nursing staff and patients' caregivers; analysis indicated that caregivers were able to manage the injections and were satisfied with the method. Assessment of pain prior to and following the injections demonstrated the effectiveness of this method in controlling patients' pain.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10661066     DOI: 10.1177/104990919901600407

Source DB:  PubMed          Journal:  Am J Hosp Palliat Care        ISSN: 1049-9091            Impact factor:   2.500


  5 in total

1.  Intermittent subcutaneous opioids for the management of cancer pain.

Authors:  Henrique A Parsons; Abdul Shukkoor; Hue Quan; Marvin O Delgado-Guay; J Lynn Palmer; Robin Fainsinger; Eduardo Bruera
Journal:  J Palliat Med       Date:  2008-12       Impact factor: 2.947

2.  Carer administration of as-needed subcutaneous medication for breakthrough symptoms in people dying at home: the CARiAD feasibility RCT.

Authors:  Marlise Poolman; Jessica Roberts; Stella Wright; Annie Hendry; Nia Goulden; Emily Af Holmes; Anthony Byrne; Paul Perkins; Zoe Hoare; Annmarie Nelson; Julia Hiscock; Dyfrig Hughes; Julie O'Connor; Betty Foster; Liz Reymond; Sue Healy; Penney Lewis; Bee Wee; Rosalynde Johnstone; Rossela Roberts; Anne Parkinson; Sian Roberts; Clare Wilkinson
Journal:  Health Technol Assess       Date:  2020-05       Impact factor: 4.014

3.  Evaluation of the optimal positioning of subcutaneous butterfly when administering injectable opioids in cancer patients.

Authors:  Nicoleta Mitrea; Daniela Mosoiu; Julie Vosit-Steller; Liliana Rogozea
Journal:  Clujul Med       Date:  2016-10-20

4.  Promoting Excellence in Symptom Management Case Series: Case Study: A New Intervention for Rapid End-of-Life Symptom Control in the Home Setting.

Authors:  Kathryn Paez; Meegan Gregg; Charlea T Massion; Brad Macy
Journal:  J Hosp Palliat Nurs       Date:  2017-10-31       Impact factor: 1.918

5.  Tonsil-derived mesenchymal stem cell-embedded in situ crosslinkable gelatin hydrogel therapy recovers postmenopausal osteoporosis through bone regeneration.

Authors:  Gyungah Kim; Yoon Shin Park; Yunki Lee; Yoon Mi Jin; Da Hyeon Choi; Kyung-Ha Ryu; Yoon Jeong Park; Ki Dong Park; Inho Jo
Journal:  PLoS One       Date:  2018-07-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.